Shares of LivaNova PLC (NASDAQ:LIVN) have been assigned a consensus recommendation of “Hold” from the eight analysts that are presently covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, three have given a hold rating and four have assigned a buy rating to the company. The average 1-year price target among brokerages that have issued ratings on the stock in the last year is $68.67.
A number of equities analysts have issued reports on LIVN shares. BidaskClub cut LivaNova PLC from a “strong-buy” rating to a “buy” rating in a report on Monday, July 24th. Jefferies Group LLC increased their price objective on shares of LivaNova PLC from $76.00 to $80.00 and gave the stock a “buy” rating in a research note on Friday. Needham & Company LLC upgraded shares of LivaNova PLC from a “hold” rating to a “buy” rating and set a $83.00 price objective for the company in a research note on Friday. Berenberg Bank restated a “buy” rating and set a $70.00 price objective on shares of LivaNova PLC in a research note on Friday, August 11th. Finally, Piper Jaffray Companies restated an “overweight” rating and set a $75.00 price objective on shares of LivaNova PLC in a research note on Tuesday, September 12th.
Shares of LivaNova PLC (LIVN) opened at 68.42 on Friday. LivaNova PLC has a 12 month low of $40.83 and a 12 month high of $69.29. The stock has a 50 day moving average price of $62.55 and a 200 day moving average price of $57.59. The firm has a market cap of $3.34 billion, a PE ratio of 122.18 and a beta of 0.58.
LivaNova PLC (NASDAQ:LIVN) last released its earnings results on Wednesday, August 9th. The company reported $1.01 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.82 by $0.19. The firm had revenue of $321.40 million during the quarter, compared to analysts’ expectations of $315.75 million. LivaNova PLC had a return on equity of 9.08% and a net margin of 2.26%. The business’s revenue for the quarter was up .1% on a year-over-year basis. On average, equities research analysts expect that LivaNova PLC will post $3.24 EPS for the current year.
In other news, Director Daniel Jeffrey Moore sold 1,000 shares of the stock in a transaction dated Tuesday, August 15th. The shares were sold at an average price of $60.76, for a total transaction of $60,760.00. Following the completion of the transaction, the director now directly owns 58,296 shares in the company, valued at approximately $3,542,064.96. The transaction was disclosed in a document filed with the SEC, which is available at this link. Corporate insiders own 0.28% of the company’s stock.
Several institutional investors have recently bought and sold shares of LIVN. BlackRock Inc. boosted its stake in shares of LivaNova PLC by 16,157.4% during the 1st quarter. BlackRock Inc. now owns 2,592,889 shares of the company’s stock worth $127,077,000 after buying an additional 2,576,940 shares during the last quarter. FMR LLC boosted its stake in shares of LivaNova PLC by 74.9% during the 1st quarter. FMR LLC now owns 4,817,815 shares of the company’s stock worth $236,118,000 after buying an additional 2,063,196 shares during the last quarter. Koch Industries Inc. acquired a new position in shares of LivaNova PLC during the 2nd quarter worth about $1,384,000. State Street Corp boosted its stake in shares of LivaNova PLC by 74.8% during the 2nd quarter. State Street Corp now owns 1,835,428 shares of the company’s stock worth $112,345,000 after buying an additional 785,268 shares during the last quarter. Finally, Credit Suisse AG boosted its stake in shares of LivaNova PLC by 2,084.7% during the 1st quarter. Credit Suisse AG now owns 694,275 shares of the company’s stock worth $34,026,000 after buying an additional 662,496 shares during the last quarter. Institutional investors own 82.36% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: This news story was originally reported by Equities Focus and is the sole property of of Equities Focus. If you are accessing this news story on another domain, it was stolen and republished in violation of US and international trademark & copyright law. The original version of this news story can be accessed at https://www.equitiesfocus.com/2017/09/17/livanova-plc-livn-receives-consensus-rating-of-hold-from-analysts.html.
About LivaNova PLC
LivaNova PLC is a medical device company focused on the development and delivery of therapeutic solutions. The Company’s segments include Cardiac Surgery, Cardiac Rhythm Management, Neuromodulation and Other. The Cardiac Surgery segment is engaged in the development, production and sale of cardiovascular surgery products.
Receive News & Ratings for LivaNova PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LivaNova PLC and related companies with MarketBeat.com's FREE daily email newsletter.